Thursday, 13 Dec 2018

Biologic/Novel Rx

Datesort ascending Type Title Save
12 Oct 2018 Social Celltrions biosimilar rituximab was previously rejected by the FDA for manufacturing issues, but has resubmitted and will go in front of the FDA Oncologic advisory committee on wednesday for a vote. https://t.co/Q4I8AqlmxL
10 Oct 2018 Social Study from 2018 International Congress on Spondyloarthritides shows that women with ankylosing spondylitis are less responsive to biologics, were less adherent and had worse Pain, ASDAS scores vs men. Study of 359 AS pts over 5 yrs https://t.co/dVIfGM4eTF
09 Oct 2018 Social The new US-Mexico-Canada Agreement (USMCA), protects new biologic drugs from generic competition for a period of at least 10 years. Currently Canada protects biologics for 8 yrs, Mexico 5 yrs; and USAS for 12 yrs. https://t.co/2uz97EcWjt
09 Oct 2018 Social Merck signs a $117 million deal to provide the Samsung Bioepis biosimilar Renflexis (infliximab-abda) to the US Veterans Administration https://t.co/IWumGS5rcl
08 Oct 2018 Social "Therapeutic Update: Biosimilars in Rheumatology" video series features nine experts talking about biosimilars, sponsored by Sandoz, Inc. Visit RheumNow to watch: https://t.co/1vmnEJqOSi #biosimilars https://t.co/WM1EINjFGy
05 Oct 2018 Social Medical marijuana use is up 83% (46K users) in Illinois -with sales of ~$12million/month. Use lead by PTSD (4000) which surpassed fibromyalgia (3400) and cancer (2500) https://t.co/NxizLBoJeC
03 Oct 2018 Social RT @RheumNow: Often Not discussed but do you combine Otezla with a biologic (TNFi or IL-17 inhibitor) in your difficult PsA patients? Rheum…
03 Oct 2018 Social Nintedaib (OFEV) is a kinase inhibitor, FDA approved for Rx of idiopathic pulmonary fibrosis (IPF). Recent NEJM study shows no added benefit of adding sildenafil to Nintedaib in alleviating SOB in IPF. This drug is being studied in systemic sclerosis. https://t.co/V6aBoGtlhP
01 Oct 2018 Social Hear nine experts talk about biosimilars in Therapeutic Update: Biosimilars, a video series brought to viewers by Sandoz. Now available on RheumNow. https://t.co/xyqelyCd2r #sponsored #biosimilars
29 Sep 2018 Social RheumNow Week in Review is up! I wanna new Drug - Ustekinumab? https://t.co/8573kuWwxO or listen at iTunes or here https://t.co/HMMA8mQ0ue
25 Sep 2018 Social Mylan and Fujifilm have won a European Commission approval to market their Humira biosimilar called Hulio. That makes for 5 such adalimumab biosimilars (others from Amgen, Sandoz, Samsung Bioepis, Boehringer Ingelheim) https://t.co/KlgPjxhU6I
20 Sep 2018 News Unproven But Profitable Stem Cell Clinics
17 Sep 2018 Social Dermatology (EADV) Congress in Paris reports 24 wk trial results of a JAK3 inhibitor and TYK2/JAK1 inhibitor in patients with alopecial areata. The 24 wk placebo-adjusted mean improvements were 33.6 and 49.5 points (P<0.0001), evident as early as Week 6, https://t.co/zN2aGpHXWk
14 Sep 2018 Social FDA approves SC Actemra (tocilizumab) for systemic JIA (Still's disease) +/-MTX. IV TCZ was FDA approved In 2011 for SJIA. Approval is based on JIGSAW, a 52-wk study. sJIA dosing based on Weight ( <30 kg-162 mg q2wk; ≥30 162 mg qwk) https://t.co/kWXdwAh35Z
11 Sep 2018 News Out of Pocket Costs for Biosimilars - No Savings So Far
11 Sep 2018 News Cutting Oral JAK 1/2 Inhibitor Dose an Option in RA
04 Sep 2018 News Tocilizumab Equals other Biologics in Cardiovascular Risk
30 Aug 2018 Slide of the day Still's Disease Survey Results: July 2018
30 Aug 2018 News Treatment Preferences in Still’s Disease
30 Aug 2018 Social Innate immune responses induced by GM-CSF induction of NLRP3 expression and IL-1β production by neutrophils can be blocked by tofacitinib. Could tofacitinib be effective in Still's disease and other autoinflammatory disorders? https://t.co/1eynwIbl6d